| Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia (NCT07323095) | Atom Therapeutics Co., Ltd | 2026-06-30 |
| Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis (NCT07303777) | Atom Therapeutics Co., Ltd | 2026-04-23 |
| Drug-Drug Interaction Study of ABP-671 in Gout Patients (NCT07367971) | Atom Therapeutics Co., Ltd | 2026-01-23 |
| Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare (NCT07145229) | Atom Therapeutics Co., Ltd | 2025-08-26 |
| Extension Study of ABP-671 in Participants With Gout (NCT06276556) | Atom Therapeutics Co., Ltd | 2024-04-22 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers (NCT06258213) | Atom Therapeutics Co., Ltd | 2024-01-23 |
| Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout (NCT05818085) | Atom Therapeutics Co., Ltd | 2023-08-11 |
| A Study to Assess the Efficacy, Safety, and Pharmacokinetics of ABP-671 in Patients With Gout or Hyperuricemia (NCT04638543) | Atom Therapeutics Co., Ltd | 2020-11-27 |
| Study to Investigate the Effects of Food on Relative Bioavailability of ABP-671 Tablets in Healthy Subjects (NCT04303039) | Atom Therapeutics Co., Ltd | 2020-05-22 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 (NCT04060173) | Atom Therapeutics Co., Ltd | 2019-09-05 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy Subjects (NCT03906006) | Atom Therapeutics Co., Ltd | 2018-10-17 |